NCT02874287

Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether treated with hydroxychloroquine could improve therapeutic effect for patients with high-risk coronary artery disease.

Detailed description

This double blind, placebo, randomized controlled trial is going to assess if hydroxychloroquine could improve the high sensitivity C-reaction protein, blood lipid, blood glucose and blood pressure, also whether hydroxychloroquine could affect the secretion of inflammatory cytokines and the M1/M2 phenotype polarization of macrophages in patients with high-risk coronary artery disease.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine Sulfate Tablets	Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
DRUG	Placebo Tablets	Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.

Timeline

• Start date: 2017-10-08
• Primary completion: 2019-03-01
• Completion: 2019-06-01
• First posted: 2016-08-22
• Last updated: 2021-08-27

Locations

1 site across 1 country: China